|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||30.50 - 31.58|
|52 Week Range||11.65 - 36.65|
|Beta (3Y Monthly)||1.40|
|PE Ratio (TTM)||1.66|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 13) AstraZeneca plc (NYSE: AZN ) Down In The Dumps (Biotech ...
The best pharmaceutical stocks to buy have a commonality: Strong Composite Ratings and Relative Strength Ratings.
Mallinckrodt soared early Tuesday after the pharma stock outperformed quarterly views, though Eli Lilly was more muted on its mixed report.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Mallinckrodt (MNK) delivered earnings and revenue surprises of 16.67% and 0.53%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Check out the companies making headlines before the bell: Eli Lilly LLY – The drug giant reported adjusted quarterly profit of $1.39 per share, four cents above estimates, with revenue also beating Street forecasts.
On a per-share basis, the Surrey, Britain-based company said it had net income of $1.34. Earnings, adjusted for one-time gains and costs, were $2.10 per share. The results beat Wall Street expectations. ...
Mallinckrodt PLC (NYSE: MNK ) unveils its next round of earnings this Tuesday, Nov. 6. Get prepared with Benzinga's ultimate preview for Mallinckrodt's Q3 earnings. Earnings and Revenue Mallinckrodt EPS ...
October was a volatile month for the markets, and biotech stocks were no exception. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) had slipped about 17 percent in the period. This compares to S&P ...
The move follows the U.S. Environmental Protection Agency's decision last month to move forward with a $205 million plan to clean up radioactive waste.
Mallinckrodt (MNK) gets $26 million for additional funding from BARDA for pediatric studies of StrataGraft skin tissue in thermal burns.
"We are now in the next phase of this opioid crisis, where the majority of deaths arise from fentanyl.”
From paramedics to soldiers, a true synthetic blood substitute could change the world of health care. At least that’s what Kalocyte’s new CEO Elaine Haynes believes.